941685-26-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a key intermediate in the synthesis of ruxolitinib-vorinostat conjugate derivatives. These conjugates exhibit dual inhibitory activity against Janus kinase (JAK) and histone deacetylase (HDAC), making them valuable in the development of novel therapeutic agents for various diseases, including cancer and inflammatory disorders.

Upstream product

• 3680-71-5 Allopurinol 
• 7400-06-8 6-amino-5-(2,2-diethoxyethyl)pyrimidin-4-ol 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1187595-88-5 4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 950661-94-6 4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
• 950661-91-3 5-bromo-4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 950661-92-4 4-(2,4-dimethylphenyl)-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid 
• 1187594-13-3 2-[1-ethanesulfonyl-3-[4-(7-[(2-(trimethylsilyl)ethoxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl]acetonitrile 
• 1443237-69-1 4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1443237-84-0 N-(3-(5-(tetrahydrofuran-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methacrylamide 
• 1443237-83-9 3-(5-(tetrahydrofuran-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aniline 
• 1443237-82-8 5-(2,5-dihydrofuran-2-yl)-4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1443237-77-1 5-(3,6-dihydro-2H-pyran-4-yl)-4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1443237-76-0 5-bromo-4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1443237-75-9 N-(3-(5-(oxazol-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methacrylamide 
• 1443237-74-8 N-(3-(5-(pyridin-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methacrylamide 
• 1443237-73-7 N-(3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methacrylamide 

Relevant academic research and scientific papers

AN IMPROVED PROCESS FOR THE PREPARATION OF BARICITINIB

The present invention provides an improved process for the preparation of Baricitinib of formula (I),

BICYCLIC JAK INHIBITORS AND USES THEREOF

Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) and methods of using the compounds, e.g., in the treatment of immune disorders, inflammatory disorders, and cancer.

Chemical Compounds

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.

Small molecular compound

The invention provides a small molecular compound, which is characterized by being a compound shown as the following structure or pharmaceutically acceptable salt thereof, wherein G is a group with aromaticity; X is a nitrogen-containing group; R is a fluorine-containing group; and Cz is connected with a nitrogen atom in the X group. The related compounds have a good performing on inhibiting Jak kinase activity and cytobiological activity.

Pyrrole/imidazo six-membered hetero-aromatic ring compound as well as preparation method and medical application thereof

The invention relates to a pyrrole/imidazo six-membered hetero-aromatic ring compound as well as a preparation method and medical application thereof. Particularly, the invention relates to a compoundas shown by general formula (I), a preparation method t

Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof

The invention provides a pyrrolopyrimidine derivative compound as shown in a general formula (I) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorphic substance, an isotope marker, an isomer or a prodrug thereof. The invent

Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof

The invention provides a pyrrolopyrimidine derivative compound as shown in a general formula (I) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorphic substance, an isotope marker, an isomer or a prodrug thereof. The invent

SYNTHESIS PROCESS OF RUXOLITINIB

The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.

PYRROLOPYRIMIDINE CRYSTAL FOR PREPARING JAK INHIBITOR

The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.

Preparation Method For Chiral Pyrrolopyrimidine Compound

Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.